{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:21:59Z","timestamp":1791217319452,"version":"4.1.0"},"reference-count":22,"publisher":"Galenos Yayinevi","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjod"],"DOI":"10.4274\/tjod.galenos.2024.21456","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T06:59:01Z","timestamp":1718002741000},"page":"78-84","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of metformin, myoinositol and metformin-myoinositol combined treatments for polycystic ovary syndrome"],"prefix":"10.4274","volume":"21","author":[{"given":"Ceyda","family":"Karada\u011f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Sakinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zer","family":"Birge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sait","family":"Bak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Karada\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Sa\u011fn\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","unstructured":"1. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018;110:364-79.","journal-title":"Fertil Steril"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/humrep\/des028","article-title":"Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors","volume":"27","author":"Sanch\u00f3n","year":"2012","unstructured":"2. Sanch\u00f3n R, Gambineri A, Alpa\u00f1\u00e9s M, Mart\u00ednez-Garc\u00eda M\u00c1, Pasquali R, Escobar-Morreale HF. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod 2012;27:1209-16.","journal-title":"Hum Reprod"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"ref3","unstructured":"4. Zawadzki JK, Danif A. Diagnostic criteria for polycystic ovary syndrome towards a rational approach. In: Dunaif A, Givens JR, Hasetine FP, et al, (eds). Polycystic ovary syndrome. Cambridge, England: Blackwell Science 1992;377-84."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.","DOI":"10.1210\/edrv.18.6.0318"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6503a1","article-title":"Medical Eligibility Criteria for Contraceptive Use, 2016","volume":"65","author":"Curtis","year":"2016","unstructured":"6. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65:1-103.","journal-title":"MMWR Recomm Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00003081-200306000-00011","article-title":"Insulin sensitizers for polycystic ovary syndrome","volume":"46","author":"Baillargeon","year":"2003","unstructured":"7. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325-40.","journal-title":"Clin Obstet Gynecol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.fertnstert.2008.01.088","article-title":"A prospective, controlled, randomized trial","volume":"91","author":"Papaleo","year":"2009","unstructured":"8. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750-4.","journal-title":"Fertil Steril"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF00971531","article-title":"Role of inositol trisphosphate as a second messenger in signal transduction processes: an essay","volume":"13","author":"Osborne","year":"1988","unstructured":"9. Osborne NN, Tobin AB, Ghazi H. Role of inositol trisphosphate as a second messenger in signal transduction processes: an essay. Neurochem Res 1988;13:177-91.","journal-title":"Neurochem Res"},{"key":"ref9","unstructured":"10. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105-10."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1472-6823-13-47","article-title":"Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study","volume":"13","author":"Gayoso-Diz","year":"2013","unstructured":"11. Gayoso-Diz P, Otero-Gonz\u00e1lez A, Rodriguez-Alvarez MX, Gude F, Garc\u00eda F, De Francisco A, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 2013;13:47.","journal-title":"BMC Endocr Disord"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34 (Suppl 1):S62-9.","DOI":"10.2337\/dc11-S062"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","unstructured":"13. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-92.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","unstructured":"14. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347-54."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejogrb.2007.01.012","article-title":"Anti-M\u00fcllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome","volume":"134","author":"Somunkiran","year":"2007","unstructured":"15. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-M\u00fcllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007;134:196-201.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/09513590.2011.564685","article-title":"The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome","volume":"27","author":"Minozzi","year":"2011","unstructured":"16. Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27:920-4.","journal-title":"Gynecol Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1472-6483(10)60248-9","article-title":"Treatment of hirsutism with myo-inositol: a prospective clinical study","volume":"17","author":"Minozzi","year":"2008","unstructured":"17. Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17:579-82.","journal-title":"Reprod Biomed Online"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1080\/09513590903015544","article-title":"Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome","volume":"25","author":"Zacch\u00e8","year":"2009","unstructured":"18. Zacch\u00e8 MM, Caputo L, Filippis S, Zacch\u00e8 G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508-13.","journal-title":"Gynecol Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.5694\/j.1326-5377.2001.tb143439.x","article-title":"Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group","volume":"174","author":"Norman","year":"2001","unstructured":"19. Norman RJ, Kidson WJ, Cuneo RC, Zacharin MR. Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. Med J Aust 2001;174:580-3.","journal-title":"Med J Aust"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2002-020997","article-title":"Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study","volume":"88","author":"Morin-Papunen","year":"2003","unstructured":"20. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148-56.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","unstructured":"21. Nas K, T\u0171\u0171 L. A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women. Eur Rev Med Pharmacol Sci 2017;21(2 Suppl):77-82."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/09513590.2018.1540578","article-title":"Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials","volume":"35","author":"Facchinetti","year":"2019","unstructured":"22. Facchinetti F, Orr\u00f9 B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol 2019;35:198-206.","journal-title":"Gynecol Endocrinol"}],"container-title":["Journal of Turkish Society of Obstetric and Gynecology"],"original-title":[],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:42:21Z","timestamp":1718174541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tjoddergisi.org\/articles\/comparison-of-metformin-myoinositol-and-metformin-myoinositol-combined-treatments-for-polycystic-ovary-syndrome\/doi\/tjod.galenos.2024.21456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6,10]]}},"URL":"https:\/\/doi.org\/10.4274\/tjod.galenos.2024.21456","relation":{},"ISSN":["1307-699X","2149-9330"],"issn-type":[{"value":"1307-699X","type":"print"},{"value":"2149-9330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}